{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"105"}]}],"title":"No response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"149"}]}],"title":"Moderate response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"44"}]}],"title":"Good response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"201"},{"groupId":"OG001","value":"298"}],"units":"Participants"}],"description":"European League Against Rheumatism (EULAR) response is defined based on the DAS28 score and the EULAR response criteria (Van Gestel et al, 1996 and 1999). The DAS28 scale ranges from score of 0 to 10, where lower scores indicate best disease control and higher scores indicate worsening of disease. At a given visit, participants with a DAS28 score of \\< 3.2 are considered good responders if the change from baseline in their DAS28 score is \\>1.2. Participants with a DAS28 score \\>= 3.2 to 5.1 are considered moderate responders if the change from baseline in their DAS28 score is \\<=1.2 to \\>=0.6. Participants with DAS28 score \\>5.1 are considered non-responders if the change from baseline in their DAS28 score is \\<=1.2 to \\>=0.6.","groups":[{"description":"Eligible participants were administered placebo by intravenous infusion on Days 1 and 15 along with MTX 10-25 mg p.o. or parenterally once a week up to 24 weeks and were followed up to Week 104.","id":"OG000","title":"Placebo Plus Methotrexate"},{"description":"Eligible Participants were administered rituximab 1000 mg as intravenous infusion on Days 1 and 15 along with MTX 10-25 mg p.o. or parenterally once a week up to Week 24 and were followed up to Week 104.","id":"OG001","title":"Rituximab Plus Methotrexate"}],"paramType":"NUMBER","populationDescription":"The ITT population included all randomized participants who received any part of an infusion of study drug. Participants whom treatment allocation was unblinded and who received treatment prior to randomization were excluded.","reportingStatus":"POSTED","timeFrame":"Week 24","title":"Number of Participants With Good, Moderate, or no European League Against Rheumatism Responses at Week 24","type":"SECONDARY","unitOfMeasure":"participants"}